names to watch: Januvia and Galvus The FDA recently approved the first DPP-4 inhibitor, called Januvia, and the agency is expected to approve a second one, Galvus, later this year
However, individuals with pre-existing cardiovascular conditions should use caution and be closely monitored by their physician
Instead of consolidating in the hands of the dominant GLP-1 players, I think the weight loss market is starting to fragment
Results exceeded those of the placebo and some comparator arms
Your metabolism simply works differently during this stage, and thats exactly why adjusting your approach can make such a meaningful difference
But theres certainly too much of a good thing, especially if you suffer from gastroparesis already